Immunotherapy for Liver Cancer
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, characterized by a poor prognosis and rising incidence. While HCC arises from diverse etiologies and employs multiple mechanisms to evade immune surveillance, recent advances in immunotherapy have revolutionized treatment approaches. Immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 have emerged as pivotal therapies for advanced HCC, alongside promising strategies such as therapeutic cancer vaccines, engineered cytokines, and adoptive cell therapies, driven by rapid progress in synthetic biology and genetic engineering.
-
Immunotherapy for Liver Cancer (1)
Gly-His-Lys acetate
- Formula: C16H28N6O6
- Molecular Weight: 400.43
Gly-His-Lys acetate is a natural, circulating regulatory and antimicrobial tripeptide derived from extracellular matrix proteins. Gly-His-Lys acetate binds Cu2+ to support copper enzyme activation, antioxidant processes, cellular bioenergetics, and the synthesis of elastin, collagen and catecholamines. Gly-His-Lys acetate regulates cell growth, differentiation and tissue repair, and exerts regenerative, anxiolytic, anti-inflammatory, analgesic and immunosuppressive activities. Gly-His-Lys acetate induces liver degenerative changes. Gly-His-Lys acetate can be used for the research of infections, anxiety, pain-related behaviors and immune-associated liver diseases.
